Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma

Japanese Journal of Clinical Oncology

Volumn 35, Issue 8, 2005, Pages 433-438

  Maruyama, Riichiroh ^a   Shoji, Fumihiro ^a   Okamoto, Tatsuro ^a   Miyamoto, Tetsuya ^a   Miyake, Tetsuro ^a   Nakamura, Tomomi ^a   Ikeda, Jiro ^a   Aoki, Yoshiro ^a   Wataya, Hiroshi ^a   Asoh, Hiroshi ^a   Ichinose, Yukito ^a  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

Extrapleural pneumonectomy; Malignant pleural mesothelioma; Triplet chemotherapy

Indexed keywords

ASBESTOS; CISPLATIN; GEMCITABINE; NAVELBINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; JAPAN; LEUKOPENIA; LUNG RESECTION; MALE; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; NEUTROPENIA; OCCUPATIONAL EXPOSURE; PLEURA MESOTHELIOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; PNEUMONECTOMY; SURVIVAL RATE; VINBLASTINE;

EID: 24944478360     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/hyi127     Document Type: Article

References (32)

1. Statistics and Information Department MsS, Ministry of Health, Labour and Welfare of Japan. Vital Statistics of Japan 2001. Tokyo: Health and Welfare Statistics Association;2001.
2. Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet 1995;345:535-9.
3. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 1999;79:666-72.
4. Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 1997;145:211-8.
5. Murai Y. Malignant mesothelioma in Japan: Analysis of registered autopsy cases. Arch Environ Health 2001;56:84-8.
6. Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study. J Clin Oncol 1999;17:25-30.
7. Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002;87:491-6.
8. van Haarst JM, Baas P, Manegold C, Schouwink JH, Burgers JA, de Bruin HG, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 2002;86:342-5.
9. Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ, et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995;22:72-9.
10. Steele JP, Shamash J, Evans MT, Gowar NH, Tischkowitz MD, Rudd RM, et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000;18:3912-7.
11. Comella P, Frasci G, Panza N, Manzione L, De Cataldis G, Cioffi R, et al. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: Interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol 2000; 18:1451-7.
12. Hesketh PJ, Nauman CJ, Hesketh AM, LaPointe J, Fogarty K, Oo TH, et al. Unfavorable therapeutic index of cisplatin/gemcitabine/vinorelbine in advanced non-small-cell lung cancer. Clin Lung Cancer 2002;4:47-51.
13. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995;108:1122-8.
14. Travis WD CT, Corrin B, Shimosato Y, Brambilla E, and Collaborators from 14 Countries. World Health Organization. International Histological Classification of Tumors. Histological Typing of Lung and Pleural Tumors, 3rd edn. Berlin: Springer Verlag; 1999.
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
16. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982;38:143-51.
17. Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
18. Ichinose Y, Itoh K, Imamura F, Araki J, Matsumoto M, Yamamoto H, et al. Triplet combination chemotherapy of cisplatin (P), gemcitabine (G) and vinorelbine (V) with lower doses maintains a sufficient effect while avoiding toxicity in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004;23.
19. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-63;discussion 63-5.
20. Weder W, Kestenholz P, Taverna C, Bodis S, Lardinois D, Jerman M, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 2004;22:3451-7.
21. Rusch VW, Rosenzweig K, Venkatraman E, Leon L, Raben A, Harrison L, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;122:788-95.
22. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44.
23. Ardizzoni A, Rosso R, Salvati F, Fusco V, Cinquegrana A, De Palma M, et al. Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) phase II study. Cancer 1991; 67:2984-7.
24. Chahinian AP, Antman K, Goutsou M, Corson JM, Suzuki Y, Modeas C, et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 1993;11:1559-65.
25. Dirix LY, van Meerbeeck J, Schrijvers D, Corthouts B, Prove A, van Marck E, et al. A phase II trial of dose-escalated doxorubicin and ifosfamide/ mesna in patients with malignant mesothelioma. Ann Oncol 1994;5:653-5.
26. Shin DM, Fossella FV, Umsawasdi T, Murphy WK, Chasen MH, Walsh G, et al. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Cancer 1995;76: 2230-6.
27. Hunt KJ, Longton G, Williams MA, Livingston RB. Treatment of malignant mesothelioma with methotrexate and vinblastine, with or without platinum chemotherapy. Chest 1996;109:1239-42.
28. Nakano T, Chahinian AP, Shinjo M, Togawa N, Tonomura A, Miyake M, et al. Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: A pilot phase II clinical trial and pharmacokinetic profile. Cancer 1999;85:2375-84.
29. Hughes A, Calvert P, Azzabi A, Plummer R, Johnson R, Rusthoven J, et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 2002; 20:3533-44.
30. Favaretto AG, Aversa SM, Paccagnella A, Manzini Vde P, Palmisano V, Oniga F, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: A multicentric phase II study. Cancer 2003;97:2791-7.
31. Schutte W, Blankenburg T, Lauerwald K, Schreiber J, Bork I, Wollscgkaeger B, et al. A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. Clin Lung Cancer 2003;4:294-7.
32. Pinto C, Marino A, Guaraldi M, Melotti B, Piana E, Martoni A, et al. Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: A phase II study. Am J Clin Oncol 2001;24:143-7.